your market intelligence analyst
Search Results
19 results
Your search is now limited to «Chemotherapy» expert search.
BIOENGINEER.ORG 02/27/2020 11:31
This strategy can open new avenues to improve the effectiveness of therapies in thousands of patients who are currently being treated with classical radiotherapy or chemotherapy; the authors intend to test this approach in clinical trials Credit: CNIO One of the most frequent problems when treating cancer is that the tumours develop resistance to therapies, [...]
“There’s a clear connection between cancer and the gut microbiome,” began Matthew Redinbo, PhD, at the opening keynote address during the recent AACR special conference The Microbiome, Viruses, and Cancer, held in Orlando. Redinbo, a professor of chemistry, biochemistry, and microbiology at the University of North Carolina at Chapel Hill, noted that there is an […]. .
Pathological Complete Response After a Single Dose of Anti-PD-1 Therapy in Combination with Chemotherapy as a First-Line Setting in an Unresectable Locally Advanced Gastric Cancer with PD-L1 Positive and Microsatellite Instability.
Oral Maintenance Chemotherapy Using S-1/Capecitabine in Metastatic Nasopharyngeal Carcinoma Patients After Systemic Chemotherapy: A Single-Institution Experience Qiaojuan Guo,1– 3,* Mengwei Chen,4,* Hanchuan Xu,1 Tianzhu Lu,1 Han Zhou,1 Yanyan Chen,1 Jingfeng Zong,1 Yun Xu,1 Bijuan Chen,1 Bingyi Wang,1 Lili Zhu,1 Jianji Pan,1,2 Shaojun Lin1,2 1Department of Radiation Oncology, Fujian Cancer Hospital & Fujian Medical University Cancer Hospital, Fuzhou, Fujian, People’s Republic of China; 2Fujian Key Laboratory of Translational Cancer Medicine, Fuzhou, Fujian, People’s Republic of China; 3Key Laboratory of Systems Biomedicine (Ministry of Education), Shanghai Center for Systems Biomedicine, Shanghai Jiao Tong University, Shanghai, People’s Re. 02/24/2020 09:55
In addition, a phase III trial of Optune® (200 kHz) as monotherapy compared to active chemotherapy in recurrent glioblastoma patients showed TTFields to be equivalent to active chemotherapy in extending survival, associated with minimal toxicity, good quality of life, and activity within the brain (14% response rate. 02/24/2020 08:55
Conditions : Recurrent Head and Neck Squamous Cell Carcinoma; Head and Neck Cancer Stage IV Interventions : Drug: Nivolumab + Paclitaxel; Drug: Cetuximab + Paclitaxel Sponsors : Grupo Español de Tratamiento de Tumores de Cabeza y Cuello; Bristol-Myers Squibb; Apices Soluciones S.L. Not yet recruiting.

Chemicals - Agricultural

Chemicals - Industrial

Business Issues

Companies - Public

Companies - Venture Funded

Commodity Prices

Financial Results

Global Markets

Global Risk Factors

Government Agencies

Information Technologies

Legal and Regulatory

Political Entities


Strategic Scenarios



On this page, you see the results of the search you have run.  You may also view the following:

  •  Click on this drop-down menu on the right hand side of the page, to choose between the machine learning-produced Insights Reports, or the listing of concepts extracted from the results, in chart or list format. 

  •  View the number of search results returned for the search in each of your collections, and click on any of those numbers to view the entire listing of results from the chosen collection.

  •  Use the search adjustment drop-downs to change the scope, sorting, and presentation of your results.

  •  Show or hide the record’s caption (content description).

  •  Show actions that can be made with the search result record.

  •  Click on the Save button after running your search, to save it so that its results will be updated each time relevant new content is added to the designated collection. You may choose to be notified via search alerts.

Click here for more info on Search Results

Click here for more info on Machine Learning applications